Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome

Authors

  • Dongmei Lu Postgraduate College of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China; Department of Respiratory and Critical Care Medicine, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
  • Nanfang Li Hypertension Center, People’s Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, China
  • Xiaoguang Yao Hypertension Center, People’s Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, China
  • Ling Zhou Hypertension Center, People’s Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, China

DOI:

https://doi.org/10.17305/bjbms.2016.1579

Keywords:

Obstructive sleep apnea-hypopnea syndrome, hypoxia-inducible factor-1, nuclear factor-κB, surfactant protein

Abstract

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a complex chronic inflammatory respiratory disease with multiple pathogenic factors and high morbidity and mortality. Serum levels of nuclear factor-κB (NF-κB), hypoxia-inducible factor-1 alpha (HIF-1α), and surfactant protein D (SPD) were investigated in OSAHS patients, to determine their clinical significance and correlation with the pathogenesis. Patients were classified into a mild and moderate OSAHS group (n = 25) and severe OSAHS group (n = 33). Twenty healthy patients served as a control group. Peripheral blood levels of NF-κB, HIF-1α, and SPD were determined by Western blot, and a correlation analysis was performed. Severe OSAHS patients received nasal continuous positive airway pressure (nCPAP) therapy and were followed up after 2 months. NF-κB p65, HIF-1α, and SPD expression levels were determined after valid nCPAP therapy. NF-κB p65 and HIF-1α expression was significantly higher in severe OSAHS group than in the other two groups (p < 0.01), and was positively correlated with the apnea-hypopnea index (AHI) (r = 0.696, p < 0.001; r = 0.634, p < 0.001). SPD expression was significantly lower in severe OSAHS group than in the control group (p < 0.01) and mild and moderate OSAHS group (p < 0.01), and was negatively correlated with AHI (r = −0.569, p < 0.001). OSAHS pathogenesis was associated with changes in NF-κB, HIF-1α, and SPD protein expression levels. nCPAP therapy could improve the clinical characteristics of the patients, lower serum NF-κB and HIF-1α levels, and increase serum SPD levels. We conclude that OSAHS is related to the expression of NF-κB, HIF-1, and SPD.

Author Biographies

  • Dongmei Lu, Postgraduate College of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China; Department of Respiratory and Critical Care Medicine, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
    Department of Respiratory and Critical Care Medicine
  • Nanfang Li, Hypertension Center, People’s Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, China
    Hypertension Center
  • Xiaoguang Yao, Hypertension Center, People’s Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, China
    Hypertension Center
  • Ling Zhou, Hypertension Center, People’s Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, China
    Hypertension Center

References

Daulatzai MA. Role of sensory stimulation in amelioration of obstructive sleep apnea. Sleep Disord 2011;2011:596879. http://dx.doi.org/10.1155/2011/596879.

Katz ES, D'Ambrosio CM. Pathophysiology of pediatric obstructive sleep apnea. Proc Am Thorac Soc 2008;5(2):253-62. http://dx.doi.org/10.1513/pats.200707-111MG.

Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008;5(2):136-43. http://dx.doi.org/10.1513/pats.200709-155MG.

Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177(9):1006-14. http://dx.doi.org/10.1093/aje/kws342.

Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005;112(17):2660-7. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.556746.

Winnicki M, Shamsuzzaman A, Lanfranchi P, Accurso V, Olson E, Davison D, et al. Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004;17(9):783-6. http://dx.doi.org/10.1016/j.amjhyper.2004.04.011.

van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008;412(3):477-84. http://dx.doi.org/10.1042/BJ20080476.

Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, Kietzmann T, et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007;18(12):4691-7.

http://dx.doi.org/10.1091/mbc.E07-04-0391.

Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 2007;27(4):755-61. http://dx.doi.org/10.1161/01.ATV.0000258979.92828.bc.

Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI. Molecular signatures of obstructive sleep apnea in adults: A review and perspective. Sleep 2009;32(4):447-70.

Cochrane CG, Spragg R, Revak SD. Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest 1983;71(3):754-761. http://dx.doi.org/10.1172/JCI110823.

Kiefmann R, Rifkind JM, Nagababu E, Bhattacharya J. Red blood cells induce hypoxic lung inflammation. Blood 2008;111(10):5205-14. http://dx.doi.org/10.1182/blood-2007-09-113902.

Ito Y, Ahmad A, Kewley E, Mason RJ. Hypoxia-inducible factor regulates expression of surfactant protein in alveolar type II cells in vitro. Am J Respir Cell Mol Biol 2011;45(5):938-45. http://dx.doi.org/10.1165/rcmb.2011-0052OC.

Ghadiali SN, Gaver DP. Biomechanics of liquid-epithelium interactions in pulmonary airways. Respir Physiol Neurobiol 2008;163(1-3):232-43. DOI: 10.1016/j.resp.2008.04.008.

Tenner AJ, Robinson SL, Borchelt J, Wright JR. Human pulmonary surfactant protein (SP-A), a protein structurally homologous to Clq, can enhance FcR- and CR1-mediated phagocytosis. J Biol Chem 1989;264(23):13923-8.

van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, van Golde LM. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990;2(1):91-8. http://dx.doi.org/10.1165/ajrcmb/2.1.91.

Hohlfeld J, Fabel H, Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J 1997;10(2):482-91. http://dx.doi.org/10.1183/09031936.97.10020482.

Antal JM, Divis LT, Erzurum SC, Wiedemann HP, Thomassen MJ. Surfactant suppresses NF-kappa B activation in human monocytic cells. Am J Respir Cell Mol Biol 1996;14(4):374-9. http://dx.doi.org/10.1165/ajrcmb.14.4.8600942.

Phelps DS, Floros J. Localization of pulmonary surfactant proteins using immunohistochemistry and tissue in situ hybridization. Exp Lung Res 1991;17(6):985-95. http://dx.doi.org/10.3109/01902149109064330.

Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000;162(3 Pt 1):1109-14.

Stapleton RD, Dixon AE, Parsons PE, Ware LB, Suratt BT; NHLBI Acute Respiratory Distress Syndrome Network. The association between BMI and plasma cytokine levels in patients with acute lung injury. Chest 2010;138(3):568-77. http://dx.doi.org/10.1378/chest.10-0014.

Winkler C, Atochina-Vasserman EN, Holz O, Beers MF, Erpenbeck VJ, Krug N, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res 2011;12:29. DOI: 10.1186/1465-9921-12-29.

He QY, Chen BY. Sleep related breathing disorders team, respiology branch, Chinese medical association, OSAHS diagnosis and treatment guideline (revision 2011) [Article in Chinese]. Chinese J Tuberc Respir Dis 2012;35(1):9-12.

Ciccone MM, Scicchitano P, Mitacchione G, Zito A, Gesualdo M, Caputo P, et al. Is there a correlation between OSAS duration/severity and carotid intima-media thickness? Respir Med 2012;106(5):740-6. http://dx.doi.org/10.1016/j.rmed.2011.12.016.

Atkeson A, Jelic S. Mechanisms of endothelial dysfunction in obstructive sleep apnea. Vasc Health Risk Manag 2008;4(6):1327-35.

https://dx.doi.org/10.2147/VHRM.S4078.

Damiani MF, Carratù P, Quaranta VN, Resta O. Influence of obstructive sleep apnea on endothelial function in obese patients. Chest 2012;141:1639; author reply 1640. http://dx.doi.org/10.1378/chest.12-0144.

Sarada SKS, Veeramohan PH, Mathew T, Saumya S, Chitharanjan M. Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. Respir Physiol Neurobiol 2012;183(1):26-34. http://dx.doi.org/10.1016/j.resp.2012.05.016.

Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, et al. An intact canonical NF-kB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 2011;186(2):1091-6. http://dx.doi.org/10.4049/jimmunol.1002256.

Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, et al. Activation of nuclear factor kappaB in obstructive sleep apnea: A pathway leading to systemic inflammation. Sleep Breath 2006;10(1):43-50.

http://dx.doi.org/10.1007/s11325-005-0046-6.

Ciccone MM, Scicchitano P, Zito A, Cortese F, Boninfante B, Falcone VA, et al. Correlation between inflammatory markers of atherosclerosis and carotid intima-media thickness in obstructive sleep apnea. Molecules 2014;19(2):1651-62. http://dx.doi.org/10.3390/molecules19021651.

Li RC, Haribabu B, Mathis SP, Kim J, Gozal D. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 2011;184(1):124-31. http://dx.doi.org/10.1164/rccm.201012-2039OC.

Dyugovskaya L, Polyakov A, Ginsberg D, Lavie P, Lavie L. Molecular pathways of spontaneous and TNF-{alpha}-mediated neutrophil apoptosis under intermittent hypoxia. Am J Respir Cell Mol Biol 2011;45(1):154-62. http://dx.doi.org/10.1165/rcmb.2010-0025OC.

Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006;343(2):591-6. http://dx.doi.org/10.1016/j.bbrc.2006.03.015.

Carratù P, Zito A, Dragonieri S, Ciccone MM, Resta O. Effect of CPAP on cardiovascular risks in OSA patients. A 4-year follow-up, preliminary data. Sleep Breath 2016. [Epub ahead of print]. http://dx.doi.org/10.1007/s11325-016-1382-4.

Sin DD, Pahlavan PS, Man SF. Surfactant protein D: A lung specific biomarker in COPD? Ther Adv Respir Dis 2008;2(2):65-74. http://dx.doi.org/10.1177/1753465808088903.

Wirtz HR, Dobbs LG. Calcium mobilization and exocytosis after one mechanical stretch of lung epithelial cells. Science 1990;250(4985):1266-9. http://dx.doi.org/10.1126/science.2173861.

Wirtz H, Schmidt M. Ventilation and secretion of pulmonary surfactant. Clin Investig 1992;70(1):3-13. http://dx.doi.org/10.1007/BF00422930.

Massaro GD, Massaro D. Morphologic evidence that large inflations of the lung stimulate secretion of surfactant. Am Rev Respir Dis 1983;127(2):235-6.

Aderibigbe AO, Thomas RF, Mercer RR, Auten RL Jr. Brief exposure to 95% oxygen alters surfactant protein D and mRNA in adult rat alveolar and bronchiolar epithelium. Am J Respir Cell Mol Biol 1999;20(2):219-27. http://dx.doi.org/10.1165/ajrcmb.20.2.3348.

Liang S, Li N, Heizhati M, Yao X, Abdireim A, Wang Y, et al. What do changes in concentrations of serum surfactant proteins A and D in OSA mean? Sleep Breath 2015;19(3):955-62. http://dx.doi.org/10.1007/s11325-014-1106-6.

Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome

Downloads

Additional Files

Published

21-02-2017

Issue

Section

Translational and Clinical Research

Categories

How to Cite

1.
Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome. Biomol Biomed [Internet]. 2017 Feb. 21 [cited 2024 Mar. 28];17(1):47-53. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/1579